Results 11 to 20 of about 42,432 (268)

Enteral absorption of octreotide [PDF]

British Journal of Pharmacology, 1992
The somatostatin octapeptide‐analogue, octreotide, is absorbed as intact peptide from the gastrointestinal (GI) tract. In situ absorption experiments in rats confirmed our recent intubation studies in human volunteers demonstrating that the peptide has preferential absorption sites in the small intestine.
G. Flicker, Jürgen Drewe, Jacky Vonderscher, Thomas Kissel, Christoph Beglinger   +4 more
openalex   +4 more sources

Use of Octreotide in the Acute Management of Bleeding Esophageal Varices [PDF]

Canadian Journal of Gastroenterology, 1997
Acute hemorrhage from esophageal varices is a medical emergency; despite early diagnosis and treatment the associated hospital mortality remains high.
Daniel C Sadowski
doaj   +2 more sources

Octreotide [PDF]

New England Journal of Medicine, 1996
A peptide inhibiting the release of growth hormone was originally detected accidentally during studies of the distribution of growth hormone–releasing factor in the hypothalamus of rats. This peptide, called somatostatin, proved to be a cyclic peptide consisting of 14 amino acids.
Lamberts, Steven W.J., van der Lely, Aart-Jan, de Herder, Wouter W., Hofland, Leo J.   +3 more
openaire   +3 more sources

A Decade of Octreotide [PDF]

Digestion, 1999
complications following pancreatic surgery). Somatostatin analogues including octreotide have been shown to reduce pressure in the splanchnic circulation, an effect that was exploited in the management of variceal and nonvariceal hemorrhages. Despite a widespread therapeutic application, octreotide seems to be a safe drug free of major side effects ...
Beglinger C, Büchler Mw
openaire   +3 more sources

Octreotide and hepatocellular carcinoma [PDF]

British Journal of Cancer, 2007
Sir, The treatment of advanced hepatocellular carcinoma (HCC) in patients no longer eligible for surgical, percutaneous or transarterial therapies is dismal. Chemotherapy, anti-estrogens or anti-androgens, retinol derivatives or stem cell factors have been tested with poor results, and we eagerly wait for the results of ‘biologic' treatments, such ...
F. Farinati, A. Sergio, A. Baldan, P. Zucchetta, CORLETO, Vito Domenico   +4 more
openaire   +3 more sources

Somatostatin subtype-2 receptor-targeted metal-based anticancer complexes [PDF]

, 2012
Conjugates of a dicarba analogue of octreotide, a potent somatostatin agonist whose receptors are overexpressed on tumor cells, with [PtCl 2(dap)] (dap = 1-(carboxylic acid)-1,2-diaminoethane) (3), [(η 6-bip)Os(4-CO 2-pico)Cl] (bip = biphenyl, pico ...
Alejandro González-Cantó, Algueró B., Anna Massaguer, Barragán F., Barragán F., Bauer W., Carlos González, Cascini G. L., Casini A., Chaplin A. B., Charvat T. T., de Jong M., Deshmukh M. V., Dirscherl G., Dolors Carrion-Salip, D’Addona D., Fischer R., Flavia Barragán, Gariepy J., Gasser G., Gianferrara T., Gossens C., Gross A., Hodson E., Hornick C. A., Hsieh H.-P., Huang C. M., Irene Gómez-Pinto, Jakupec M. A., Jakupec M. A., Janecka A., Jennerwein M., Koradi R., Kostrhunova H., Kostrhunova H., Levina A., Liu H.-K., Marchán V., Marchán V., Melacini G., Metzler-Nolte N., Mezo G., Moradell S., Moreno V., Morris R. E., Mukhopadhyay S., Novakova O., Okarvi S. M., Peacock A. F. A., Peacock A. F. A., Peacock A. F. A., Peindy N’Dongo H. W., Peter J. Sadler, Pizarro A. M., Puckett C. A., Rademaker-Lakhai J. M., Rafael de Llorens, Reubi J. C., Reubi J. C., Schaer J. C., Singh S. K., Splith K., Sun L.-C., Süss-Fink G., van Rijt S. H., van Rijt S. H., van Rijt S. H., van Rijt S. H., Vicente Marchán, Virtudes Moreno, Wang F., Wang F., Watson J. C., Wheate N. J., Wynants C., Wynants C., Zaccaro L., Zhang J., Zhang Y.   +78 more
core   +5 more sources

Natural History and Management of Familial Paraganglioma Syndrome Type 1: Long-Term Data from a Large Family [PDF]

, 2020
Head and neck paragangliomas are the most common clinical features of familial paraganglioma syndrome type 1 caused by succinate dehydrogenase complex subunit D (SDHD) mutation. The clinical management of this syndrome is still unclear.
Cantisani, Vito, Colao, Annamaria, Di Leo, Nicola, Faggiano, Antongiulio, Feola, Tiziana, Giannetta, Elisa, Isidori, Andrea M, Lenzi, Andrea, Modica, Roberta, Polti, Giorgia, Puliani, Giulia, Sesti, Franz, Verrico, Monica   +12 more
core   +1 more source

Therapeutic applications of octreotide in pediatric patients

The Saudi Journal of Gastroenterology, 2012
Background/Aim: We report our experience with the use of octreotide as primary or adjunctive therapy in children with various gastrointestinal disorders.
Abdulrahman Al-Hussaini, Decker Butzner
doaj   +1 more source

Pharmacological Treatment of Postprandial Reductions in Blood Pressure : A Systematic Review [PDF]

, 2015
Funded by The Dunhill Medical Trust.
Alam, Aronow, Freeman, Gentilcore, Heseltine, Heseltine, Hirayama, Jansen, Jansen, Jansen, Jansen, Jian, Jones, Jones, Lenders, Lipsitz, Lipsitz, Moher, O'Donovan, Onrot, Potter, Rakic, Russo, Sawynok, Shibao, Vaitkevicius, Visvanathan, Vloet, Vloet   +28 more
core   +1 more source

Growth Hormone (GH)-Releasing Peptide Stimulation of GH Release from Human Somatotroph Adenoma Cells: Interaction with GH-Releasing Hormone, Thyrotropin- Releasing Hormone, and Octreotide. [PDF]

, 1994
The synthetic hexapeptide GH-releasing peptide (GHRP; His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) specifically stimulates GH secretion in humans in vivo and in animals in vitro and in vivo via a still unknown receptor and mechanism.
Brockmeier, S., Lange, M., Müller, Otto-Albrecht, Renner, U., Schopohl, Jochen, Stalla, G. K., Strasburger, Christian J., Werder, K. von   +7 more
core   +1 more source